DrugPatentWatch Database PreviewSee Plans and Pricing
« Back to Dashboard
Fexinidazole is an investigational drug.
There have been 12 clinical trials for Fexinidazole. The most recent clinical trial was a Phase 1 trial, which was initiated on November 1st 2016.
The most common disease conditions in clinical trials are Trypanosomiasis, Trypanosomiasis, African, and Chagas Disease. The leading clinical trial sponsors are Drugs for Neglected Diseases, Sanofi, and European and Developing Countries Clinical Trials Partnership (EDCTP).
There are twenty US patents protecting this investigational drug and one hundred and eighty-three international patents.
Recent Clinical Trials for Fexinidazole
|Efficacy and Safety of Fexinidazole in Patients With Human African Trypanosomiasis (HAT) Due to Trypanosoma Brucei Rhodesiense||European and Developing Countries Clinical Trials Partnership (EDCTP)||Phase 2/Phase 3|
|Efficacy and Safety of Fexinidazole in Patients With Human African Trypanosomiasis (HAT) Due to Trypanosoma Brucei Rhodesiense||Drugs for Neglected Diseases||Phase 2/Phase 3|
|Oral Fexinidazole Dosing Regimens for the Treatment of Adults With Chronic Indeterminate Chagas Disease||Drugs for Neglected Diseases||Phase 2|
Top disease conditions for Fexinidazole
Top clinical trial sponsors for Fexinidazole
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|Fexinidazole||Start Trial||Boron-containing small molecules as antiprotozoal1 agents||MMV MEDICINES FOR MALARIA VENTURE (Geneva, CH)||Start Trial|
|Fexinidazole||Start Trial||Controlled release dosage form||TRIASTEK, INC. (Nanjing, CN)||Start Trial|
|Fexinidazole||Start Trial||Oral drug dosage forms having desired drug release profiles and uses thereof||Triastek, Inc. (Nanjing, CN)||Start Trial|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|